Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies.
Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies.
复制标题
选择性血清素再摄取抑制剂（SSRI）和先天性心脏缺陷的风险：前瞻性队列研究的荟萃分析。
DOI：
10.1161/jaha.114.001681
复制
发表时间：
2015-05-19
影响因子：
5.4
通讯作者：
Xiong Y
中科院分区：
文献类型：
--
作者：
Wang S;Yang L;Wang L;Gao L;Xu B;Xiong Y
最近的研究报告了选择性血清素再摄取抑制剂（SSRI）与心脏缺陷风险之间关系的相互矛盾的结果。我们的目的是评估孕妇在妊娠前三个月服用 SSRIs 与先天性心脏病风险之间的关系。 PubMed 和 EMBASE 检索了截至 2014 年 7 月的基于人群的队列研究，这些研究报告了孕妇在妊娠早期使用 SSRIs 以及随访时活婴的心脏缺陷情况。主要通过固定效应模型对已发表的数据进行荟萃分析。四项队列研究共纳入 1 996 519 名参与者，平均随访期从出院到 72 个月不等。 SSRIs 与心脏缺陷风险增加无关 1.06（95% 置信区间：0.94 至 1.18）。孕妇在妊娠前三个月服用 SSRIs 与新生儿心脏缺陷风险增加无关。
Recent studies have reported conflicting results on the association between selective serotonin reuptake inhibitors (SSRIs) and the risk of heart defects. We aimed to assess the association between SSRIs in pregnant women during the first trimester and the risk of congenital heart defects. PubMed and EMBASE up to July 2014 were searched for population-based cohort studies that reported SSRIs in pregnant women during the first trimester and live infants’ heart defects at follow-up. A meta-analysis of published data was undertaken primarily by means of fixed-effects models. Four cohort studies including 1 996 519 participants were included with a mean follow-up period ranging from discharge to 72 months. SSRIs were not associated with increased risks of heart defects 1.06 (95% confidence interval: 0.94 to 1.18). SSRIs during the first trimester in pregnant women were not associated with increased risks for newborn heart defects.